Biogen Inc.
BIIB
$147.37
$3.602.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.45B | 2.47B | 2.46B | 2.29B | 2.39B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.45B | 2.47B | 2.46B | 2.29B | 2.39B |
| Cost of Revenue | 583.50M | 638.70M | 501.90M | 498.10M | 618.30M |
| Gross Profit | 1.87B | 1.83B | 1.96B | 1.79B | 1.77B |
| SG&A Expenses | 678.70M | 576.90M | 550.30M | 578.30M | 608.10M |
| Depreciation & Amortization | 91.00M | 130.30M | 86.90M | 78.30M | 76.60M |
| Other Operating Expenses | 57.10M | 69.30M | 62.40M | 65.60M | 54.30M |
| Total Operating Expenses | 1.93B | 1.95B | 1.66B | 1.67B | 1.93B |
| Operating Income | 527.90M | 511.40M | 801.00M | 624.90M | 461.10M |
| Income Before Tax | 291.50M | 451.00M | 698.70M | 464.80M | 291.60M |
| Income Tax Expenses | 24.80M | 62.50M | 115.10M | 71.40M | 42.70M |
| Earnings from Continuing Operations | 266.70M | 388.50M | 583.60M | 393.40M | 248.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 800.00K |
| Net Income | 266.70M | 388.50M | 583.60M | 393.40M | 249.70M |
| EBIT | 527.90M | 511.40M | 801.00M | 624.90M | 461.10M |
| EBITDA | 711.90M | 694.20M | 959.90M | 772.40M | 601.20M |
| EPS Basic | 1.83 | 2.67 | 4.01 | 2.71 | 1.72 |
| Normalized Basic EPS | 2.35 | 1.96 | 3.20 | 2.42 | 1.72 |
| EPS Diluted | 1.82 | 2.66 | 4.00 | 2.70 | 1.71 |
| Normalized Diluted EPS | 2.34 | 1.96 | 3.20 | 2.41 | 1.71 |
| Average Basic Shares Outstanding | 145.70M | 145.70M | 145.60M | 145.20M | 144.90M |
| Average Diluted Shares Outstanding | 146.10M | 146.10M | 145.90M | 145.90M | 145.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
